Vol. 2 No. 1 (2025)

Research Articles

Potential Collaborative Markers for Nasopharyngeal Carcinoma Diagnosis and Therapy: AGR2 and AKR1B10

Published 2025-05-31

  • Qi Tang
    • ,
  • Yao Wu
    • ,
  • Yuan Tan
    • ,
  • Faqing Tang

Qi Tang
The First Hospital of Hunan University of Chinese Medicine & Hunan Cancer Hospital, Changsha, 410007, China

Yao Wu
The First Hospital of Hunan University of Chinese Medicine & Hunan Cancer Hospital, Changsha, 410007, China

Yuan Tan
Department of Clinical Laboratory and Hunan Key Laboratory of Oncotarget gene, The affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.


Faqing Tang
The First Hospital of Hunan University of Chinese Medicine & Hunan Cancer Hospital, Changsha, 410007, China; Department of Clinical Laboratory and Hunan Key Laboratory of Oncotarget gene, The affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China.


Abstract

Nasopharyngeal carcinoma is a prevalent malignant tumor, which lacks specific diagnostic markers and effective therapeutic evaluation indexes. AGR2 (Pregradient protein 2) and AKR1B10 (aldoketone reductase 1B10) are oncoproteins secreted by cancer cells into peripheral blood. Prior researches have suggested that the upregulation of AGR2 and AKR1B10 occurs in both primary and metastatic NPC tissues, indicating their potential as biomarkers for NPC development. In the present study, NPC patients had considerably greater serum levels of AGR2 and AKR1B10 than did healthy persons, and these levels decreased following treatment. Furthermore, the serum concentrations of AGR2 and AKR1B10 in patients with NPC were positively correlated with the grade of TNM (tumor lymph node metastasis) and the occurrence of meta stasis. Consistently, AGR2 and AKR1B10 positive rates in NPC tissues were notably greater than those in nearby normal tissues. Additionally, there was an affirmative linear connection between AGR2 and AKR1B10 in NPC patients. In conclusion, there appears to be a close relationship between the expression of AGR2 and AKR1B10, both serving as synergistic biomarkers for early diagnosis and treatment evaluation indicators for patients with nasopharyngeal carcinoma.

Keywords

AGR2, AKR1B10, collaborative biomarkers , diagnosis, nasopharyngeal carcinoma

PDF

References

  1. Yang, M. and W. Huang. Circular RNAs in Nasopharyngeal Carcinoma. Clin Chim Acta. 2020.
  2. Kontny, U., S. Franzen, U. Behrends, et al. Diagnosis and Treatment of Nasopharyngeal Carcinoma in Children and Adolescents - Recommendations of the GPOH-NPC Study Group. Klin Padiatr. 2016; 228(3): 105-12.
  3. Feng, B.J., W. Huang, Y.Y. Shugart, et al. Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4. Nat Genet. 2002; 31(4): 395-9.
  4. Verma, N., S. Patel, V. Osborn, et al. Prognostic significance of human papillomavirus and Epstein-Bar virus in nasopharyngeal carcinoma. Head Neck. 2020.
  5. Bei, J.X., X.Y. Zuo, W.S. Liu, Y.M. Guo, and Y.X. Zeng. Genetic susceptibility to the endemic form of NPC. Chin Clin Oncol. 2016; 5(2): 15.
  6. Imamura, M., T. Kawai, S. Okada, et al. Disseminated BCG infection mimicking metastatic nasopharyngeal carcinoma in an immunodeficient child with a novel hypomorphic NEMO mutation. J Clin Immunol. 2011; 31(5): 802-10.
  7. Simons, M.J. Nasopharyngeal carcinoma as a paradigm of cancer genetics. Chin J Cancer. 2011; 30(2): 79-84.
  8. Xu, T., B. Su, P. Huang, et al. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load. Proteomics Clin Appl. 2017; 11(5-6).
  9. Li, Y., J. Lu, Z. Peng, et al. N,N'-dinitrosopiperazine-mediated AGR2 is involved in metastasis of nasopharyngeal carcinoma. PLoS One. 2014; 9(4): e92081.
  10. He, Y.C., Y. Shen, Y. Cao, et al. Overexpression of AKR1B10 in nasopharyngeal carcinoma as a potential biomarker. Cancer Biomark. 2016; 16(1): 127-35.
  11. Jia, M., Y. Guo, D. Zhu, et al. Pro-metastatic activity of AGR2 interrupts angiogenesis target bevacizumab efficiency via direct interaction with VEGFA and activation of NF-kappaB pathway. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(5 Pt A): 1622-1633.
  12. Vitello, E.A., S.I. Quek, H. Kincaid, et al. Cancer-secreted AGR2 induces programmed cell death in normal cells. Oncotarget. 2016; 7(31): 49425-49434.
  13. Guo, J., G. Gong, and B. Zhang. Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray. Tumour Biol. 2017; 39(7): 1010428317713392.
  14. Sung, H.Y., E.N. Choi, D. Lyu, et al. Aberrant hypomethylation-mediated AGR2 overexpression induces an aggressive phenotype in ovarian cancer cells. Oncol Rep. 2014; 32(2): 815-20.
  15. Milewski, D., D. Balli, V. Ustiyan, et al. FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genet. 2017; 13(12): e1007097.
  16. Zhang, J., Y. Jin, S. Xu, et al. AGR2 is associated with gastric cancer progression and poor survival. Oncol Lett. 2016; 11(3): 2075-2083.
  17. Tian, S., J. Hu, K. Tao, et al. Secreted AGR2 promotes invasion of colorectal cancer cells via Wnt11-mediated non-canonical Wnt signaling. Exp Cell Res. 2018; 364(2): 198-207.
  18. Alavi, M., V. Mah, E.L. Maresh, et al. High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer. 2015; 15: 655.
  19. Huang, L., R. He, W. Luo, et al. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment. Recent Pat Anticancer Drug Discov. 2016; 11(2): 184-96.
  20. Ma, J., D.X. Luo, C. Huang, et al. AKR1B10 overexpression in breast cancer: association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. Int J Cancer. 2012; 131(6): E862-71.
  21. Shi, J., L. Chen, Y. Chen, et al. Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma. J Cancer. 2019; 10(20): 4892-4901.
  22. Fang, C.Y., Y.H. Lin, and C.L. Chen. Overexpression of AKR1B10 predicts tumor recurrence and short survival in oral squamous cell carcinoma patients. J Oral Pathol Med. 2019; 48(8): 712-719.
  23. Hung, J.J., Y.C. Yeh, and W.H. Hsu. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma. Thorac Cancer. 2018; 9(11): 1492-1499.
  24. Ahmed, S.M.U., Z.N. Jiang, Z.H. Zheng, et al. AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncol Lett. 2019; 17(1): 773-780.
  25. Li, J., J. Hu, Z. Luo, et al. AGR2 is controlled by DNMT3a-centered signaling module and mediates tumor resistance to 5-Aza in colorectal cancer. Exp Cell Res. 2019; 385(1): 111644.
  26. Dumartin, L., W. Alrawashdeh, S.M. Trabulo, et al. ER stress protein AGR2 precedes and is involved in the regulation of pancreatic cancer initiation. Oncogene. 2017; 36(22): 3094-3103.
  27. Fessart, D., C. Domblides, T. Avril, et al. Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties. Elife. 2016; 5.
  28. Pan, F., W. Yang, W. Li, et al. Conjugation of gold nanoparticles and recombinant human endostatin modulates vascular normalization via interruption of anterior gradient 2-mediated angiogenesis. Tumour Biol. 2017; 39(7): 1010428317708547.
  29. Worfolk, J.C., S. Bell, L.D. Simpson, et al. Elucidation of the AGR2 Interactome in Esophageal Adenocarcinoma Cells Identifies a Redox-Sensitive Chaperone Hub for the Quality Control of MUC-5AC. Antioxid Redox Signal. 2019; 31(15): 1117-1132.
  30. Alsereihi, R., H.J. Schulten, S. Bakhashab, et al. Leveraging the Role of the Metastatic Associated Protein Anterior Gradient Homologue 2 in Unfolded Protein Degradation: A Novel Therapeutic Biomarker for Cancer. Cancers (Basel). 2019; 11(7).
  31. Li, J., Y. Guo, L. Duan, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 2017; 8(20): 33694-33703.
  32. Sommerova, L., E. Ondrouskova, B. Vojtesek, and R. Hrstka. Suppression of AGR2 in a TGF-beta-induced Smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer. 2017; 17(1): 546.
  33. Sun, X.S., Y.J. Liang, S.L. Liu, et al. Subdivision of Nasopharyngeal Carcinoma Patients with Bone-Only Metastasis at Diagnosis for Prediction of Survival and Treatment Guidance. Cancer Res Treat. 2019; 51(4): 1259-1268.
  34. Li, W., Y. Bai, M. Wu, et al. Combined CT-guided radiofrequency ablation with systemic chemotherapy improves the survival for nasopharyngeal carcinoma with oligometastasis in liver: Propensity score matching analysis. Oncotarget. 2017; 8(32): 52132-52141.
  35. Curtarelli, R.B., J.M. Goncalves, L.G.P. Dos Santos, et al. Expression of Cancer Stem Cell Biomarkers in Human Head and Neck Carcinomas: a Systematic Review. Stem Cell Rev Rep. 2018; 14(6): 769-784.
  36. Pan, F., W. Li, W. Yang, et al. Anterior gradient 2 as a supervisory marker for tumor vessel normalization induced by anti-angiogenic treatment. Oncol Lett. 2018; 16(3): 3083-3091.
  37. Li, Y., W. Wang, Z. Liu, et al. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis. Clin Chim Acta. 2018; 484: 323-327.
  38. DiStefano, J.K. and B. Davis. Diagnostic and Prognostic Potential of AKR1B10 in Human Hepatocellular Carcinoma. Cancers (Basel). 2019; 11(4).
  39. Geng, N., Y. Jin, Y. Li, S. Zhu, and H. Bai. AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma. Int J Med Sci. 2020; 17(9): 1246-1256.
  40. Liu, R., M. Qian, T. Zhou, and P. Cui. TP53 mediated miR-3647-5p prevents progression of cervical carcinoma by targeting AGR2. Cancer Med. 2019; 8(13): 6095-6105.
  41. Negi, H., S.B. Merugu, H.B. Mangukiya, et al. Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study. Cancer Lett. 2019; 449: 125-134.
  42. Lee, H.J., C.Y. Hong, C.J. Jin, et al. Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer. Cell Mol Immunol. 2012; 9(2): 175-83.
  43. Liu, A.Y., A.D. Kanan, T.P. Radon, et al. AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting. Oncotarget. 2019; 10(42): 4276-4289.